Print

KineMed, Inc. Announces Biomarker Discovery Collaboration With GlaxoSmithKline (GSK)  
6/18/2012 7:50:00 AM

EMERYVILLE, Calif.--(BUSINESS WIRE)-- KineMed, Inc. (www.kinemed.com) announced today a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) (LSE: GSK, NYSE: GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable more informed and timely decision-making in clinical trials of compounds for muscle wasting, fibrosis and metabolic diseases.

David Fineman, President & CEO of KineMed, said, “We are delighted to announce this collaboration. The marriage of KineMed’s insights into biology with GSK’s clinical portfolio marks the start of an exceptional initiative to advance innovative evidence-based medicines.”

Marc Hellerstein, M.D., Ph.D., Chief of the Scientific Advisory Board of KineMed, stated: “Our shared goal with GSK is to identify causal pathways and kinetic signatures that can better inform drug development decisions. The missing links in developing drugs to treat muscle wasting, fibrosis and metabolic diseases have been reliable biomarkers that measure the degree to which we are having therapeutic impact on their underlying disease processes. KineMed’s technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them.”

About KineMed, Inc.

KineMed, Inc. is a biomarker discovery and development company based in Emeryville, California. Our biomarkers provide predictive, actionable information to dramatically improve, de-risk and accelerate drug discovery, development and disease management decisions.

KineMed’s established, proprietary platform assists pharmaceutical collaborators by revealing the mechanism of action of complex diseases and providing quantitative measures of the effects of drugs on these causal processes. Our biomarkers are fully translational from animal to man, seamlessly harmonizing data across pre-clinical and clinical phases of development, through to the diagnosis and management of disease.

KineMed’s platform addresses key industry needs:

•Focus on causes rather than symptoms: Generating pivotal knowledge for developing novel therapeutics that are differentiated by targeting underlying biochemical causes

•Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context

•Reduce late-stage attrition: Early, decision-relevant metrics of drug activity separate winners from losers and reduce later failures to improve the NPV of R&D spend

•Powerful assays of disease state: Custom-developed assays create companion diagnostic tests for personalized medicine

In addition to assisting clients, KineMed also has an active pipeline of therapeutics and diagnostics in development.

KineMed is seeking further broad collaborations with biotechnology, pharmaceutical, CRO, histopathology, diagnostics and medical instrument partners.

For more information about KineMed, please visit: http://www.kinemed.com

Contact:

KineMed, Inc.

Ravi Kiron, Ph.D., Chief Business Officer

510-655-6525 ext. 105 rkiron@kinemed.com


//-->